Dov Pharmaceutical Inc. has been slowing dying for a long time, but its neglected assets are now back in play in newco Euthymics Bioscience Inc., which VCs financed with $24 million in a tranched series A round last week.

At the same time, Euthymics completed its merger into Dov, which was announced in February, but taking it private instead of keeping the public listing.